JAK2 and COVID-19: Ruxolitinib is an oral, selective JAK1/JAK2 inhibitor with clinical activity in hemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome with a macrophage‐derived cytokine profile similar to that observed in COVID‐19 [5, 6, 7].